Investment activity surrounding
Charles River Laboratories International, Inc. (CRL) showcases mixed sentiment recently. Various asset management companies have adjusted their stakes. For instance,
Assenagon Asset Management, JP Morgan Chase & Co., and Natixis Advisors LLC increased their stakes, while
Riverbridge Partners LLC, Meridiem Capital Partners LP, Iron Triangle Partners LP, and Mackenzie Financial Corp decreased their holdings.
SG Americas Securities LLC and Earnest Partners LLC invested significantly. Amid a fluctuating trading performance, down 6.8% since the last earnings report, CRL has consistently outperformed its competitors on strong trading days. There's investor interest in CRL's
international revenue trends and its strategy for Asia-Pacific growth, especially following its tie-up with Locus Cell. Controversially, the company faces
an investigation by Kahn Swick & Foti, LLC and an
earnings cut and planned divestitures appear to have somewhat dampened investor confidence. Nevertheless, CRL's performance has improved recently, earning an
Outperform rating from Baird, as well as outshining peers again on the market. Upcoming fiscal results and potential changes in leadership could significantly impact CRL's performance.
Charles River Laboratories International CRL News Analytics from Tue, 15 Jul 2025 07:00:00 GMT to Sat, 28 Mar 2026 07:28:35 GMT -
Rating 2
- Innovation -5
- Information 7
- Rumor -8
